Cancer researchers around the world now have a powerful new tool at their fingertips that provides instant access to information on ongoing cancer research supported by cancer funding organizations within the United States and the United Kingdom.

The National Cancer Institute (NCI) today announced plans to fund four Centers of Excellence in Cancer Communications Research (CECCR). The CECCR initiative is the centerpiece of NCI’s Extraordinary Opportunity in Cancer Communications (EOCC), a broad initiative that supports research and outreach aimed at increasing the knowledge about, tools for, access to, and use of cancer […]

NCI Announces Results of Prostate Cancer Prevention Trial
Men who took finasteride, a drug that affects male hormone levels, reduced their chances of getting prostate cancer by nearly 25 percent compared to men who took a placebo, according to results of a national study released today online by the New England Journal of Medicine.

Scientists at the National Cancer Institute (NCI) have found a new method for modifying the immune system of cancer patients to induce cancer regression. Inhibiting a molecule known as cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), which has a critical role in regulating the immune response, can enable the immune system to attack some patients’ tumors, […]

The Hispanic/Latino Genetics Community Consultation Network (HLGCCN) summit meeting, a first of its kind conference, will be held in Washington, D.C., from June 22 to 24, 2003. Supported by the National Institutes of Health (NIH), it will feature 75 key opinion leaders and genetics experts from Hispanic/Latino communities across the United States who will explore […]

Since the use of highly active antiretroviral therapy (HAART) to treat HIV, physicians have seen an improvement in the prognosis for patients with AIDS-related lymphomas. Researchers from the National Cancer Institute (NCI) have now identified a biological basis for this change. The results of the new study, reported in the June 15, 2003, issue of […]

The National Cancer Institute (NCI) today announced that it is planning to open a clinical trial that will evaluate bevacizumab (Avastinâ„¢), an antiangiogenic agent, for patients with metastatic colorectal cancer who are no longer benefiting from effective, standard treatment regimens. Patients in this trial will receive bevacizumab in combination with 5-fluorouracil (5FU) and leucovorin.

In patients with metastatic breast cancer, immune cells from a genetically matched donor can attack and shrink tumors, researchers from the National Cancer Institute (NCI) announced today at the Annual Meeting of the American Society of Clinical Oncology in Chicago. This is the first time researchers have clearly demonstrated this type of immune response, known […]